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Introduction
Perfluorochemicals can dissolve significant quantities of many 
gases including oxygen (O2) and carbon dioxide (CO2). Optimal use 
of artificial blood substitutes such as perfluorocarbon emulsions in 
conjunction with 100% oxygen ventilation are valuable to patients 
with relatively low hemoglobin levels (e.g. sickle cell anemia patients 
or patients suffering of surgical blood loss.1-4. Indeed, they can help to 
enhance oxygen tissue delivery, reduce allogeneic blood transfusion 
requirement which consequently reduce potential infections (e.g. 
hepatitis, HIV) [1-4].  
Perfluorochemicals are hydrophobic, then stable perfluorocarbon 
emulsion with exceptionally smaller particles (median diameter 
< 0.2 μm) than red blood cells (median diameter ~ 7 µm) have 
been generated for intravenous use [5]. Thereby, perfluorocarbon 
molecules such as perfluorobron (also referred to as perfluorooctyl 
bromide or bromoperfluoro-n-octane, C8F17Br) or perfluodecalin (aka 
octadecafluoronaphthalene, C10F18) represent the main component 
of commercialized artificial blood substitutes Oxygent® (Alliance 
Pharmaceutical Corporation, San Diego, California, USA) [5] and 
Fluosol® (Green Cross Corporation, Osaka, Japan) [6], respectively. 
In fact, perfluorobron (PFB) and perfluorodecalin (PFD) are the most 
used components in formulations [7].
While the metabolism of fluorocarbon molecules is still unclear in 
humans, it seems that after intravenous administration, the droplets 
of perfluorocarbon emulsions are taken up by the reticulo-endothelial 
system (RES) before being slowly broken down and transported by 
the blood to the lungs where the unaltered perfluorocarbon molecules 
are finally excreted via exhalation [8,9]. The intravascular half-life of 
perfluorocarbons, determined by the RES uptake and the dose used, is 
relatively short (< 24 hours) [10,11].
Up-to-date, Fluosol® is the only blood substitute product approved 
by the U.S. Food and Drug Administration (FDA) for clinical use 
(e.g. supplemental oxygenation of ischemic tissue in percutaneous 
transluminal coronary angioplasty (PTCA) because of its ability to 
diffuse into poorly vascularized tissue [12].
In order to characterize qualitatively and quantitatively 
perfluorocarbons and its derived products (e.g. metabolized ones), we 
used an innovative and powerful technology named carbon-fluorine 
spectroscopy (CFS™) [13,14]. In fact, CFS™ is a progressive, non-
destructive and non-invasive laser-based technology, which based on 
the discovery of a characteristic signature of carbon-fluorine (C-F) 
bond(s) in the fingerprint spectral area of 550-850 cm-1, allows fast, 
sensitive and specific detection as well as structural characterization, 
imaging, screening, tracking and quantitative determination of any 
fluoro-organics, regardless their physical state [13,14].
In this study, we report the by CFS™ spectral profiling of two major 
PFCs, PFB and PFD, obtained by under different in vitro experimental 
conditions. 
Abstract
Blood substitutes, aka artificial oxygen carriers, such as perfluorocarbon emulsions, aim at improving oxygen 
transport and oxygen unloading to the tissue. Thereby, artificial oxygen carriers can replace allogeneic blood 
transfusions and improve tissue oxygenation, subsequently contributing to the function of organs with marginal 
oxygen supply. Carbon-Fluorine Spectroscopy (CFS™) aka Spectro-Fluor™ patented by Fluorotronics, Inc., is a 
green, disruptive, non-destructive, non-invasive and progressive analytical technology that was shown reliable and 
promising for various (nano-) pharmaceutical and bio-medical applications. The key feature of CFS™ is based on 
the capability to specifically, sensitively and rapidly detect carbon-fluorine bond(s) in the fingerprint spectral area of 
550-850 cm-1 allowing F-imaging as well as qualitative and quantitative characterization of fluoro-organics in vitro, 
ex-vivo or in-vivo.
In this study, we show perfluorocarbons (PFCs), such as perfluorobron (PFB) and perfluorodecalin (PFD) can 
be easily, reliably and rapidly detected by CFS™ in various containers, especially under visible excitation (510.6 
nm), opening a possible avenue for enhancing blood substitutes product security (anti-counterfeiting) or performing 
advanced metabolic and toxicological studies of these compounds in vivo (e.g. pharmacokinetics, bioavailability). 
Indeed, the range of specific signal wavelength related to the C-F bond in PFCs was besides confirmed by density 
functional theory (DFT) calculations.
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Material and Methods
Fluoro-materials
Undiluted main components of liquid blood substitutes, pure 
perfluorobron (C18F17Br) and pure perfluorodecalin (C10F18) were 
obtained from Alliance Pharmaceutical Corp. (San Diego, CA, USA) 
and Green Cross Corporation (Osaka, Japan), respectively. Their 
respective optimized structure determined by DFT calculations are 
presented in Figure 1. 
Perfluorocarbons analysis by CFS™ technology 
The detailed development, work system and features of the CFS™ 
technology have been previously described [13]. Fluoro-Raman spectra 
of those compounds were obtained, in several experimental conditions 
and the reliability of the data was confirmed by at least two independent 
experiments. Thereby, the samples have been placed either into (i) glass 
container (Figure 2), (ii) flow cell (Agilent) (Figure 3), (iii) high power 
fiber optics (Figure 4). The general set-up of CFS was performed in 
order to detect Raman spectra at 90 degrees with respect to the incident 
pulse using a pulsed copper vapor laser (CrystalTechno, Moscow, 
Russia) and a double monochromator (Jobin Yvon). The main set-
up parameters were the following: (i) excitation at 510.6 nm (visible 
region) or 271.2 nm (ultraviolet (UV) region to observe resonance 
CFS™ spectra), (ii) repetition rate of 10 kHz, (iii) pulse duration of 17 
ns and, (iv) average power of 200 mW. Globally, the high energy laser 
pulses irradiated the fluoro-organic sample and the consequent Raman 
vibrational scattering emissions were detected during a narrow time 
internal (‘‘gate’’) approximately equal to the laser pulse duration, so the 
CFS™ spectrum was not affected by fluorescence. The absorbance filter 
removed scattered radiation and passed the pulsed Raman radiation 
to the spectrometer. Eventually, signals were photo-multiplied and 
sent to a synchronized pulse recording system. The data were collected 
on computer and processed using the software-time resolved Solis(t) 
(Andor, Northern Ireland) and the software package Spectramax 
(Jobin Yvon). 
DFT Calculations
All the density functional theory (DFT) calculations reported 
herein were performed with Gaussian 03 software package [15]. 
Ground state structure was obtained by carrying out a full geometry 
optimizations with  DFT/6-31G (d)  basis set using hybrid Becke's 3 
Parameter exchange functional and Lee, Yang and Parr correlation 
functional (B3LYP). Raman spectra were calculated on the optimized 
geometry. Since B3LYP level overestimate the calculated vibrational 
frequency due to neglect of anharmonicity in real system, a scaling 
factor of 0.9613 [16] has been used to produce good agreement with 
experiment. We have not observed any imaginary frequency which 
suggested that the molecule was in local minimum on the potential 
energy surface. 
A                                                                          B
Figure 1: Optimized structure of (A) perfluorobron (C8F17Br) and (B) 
perfluorodecalin (C10F18) obtained by DFT calculations.
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Figure 2: CFS spectrum of undiluted liquid blood substitute, perfluorobron, 
measured via glass container at 510.6 nm.
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Figure 3: CFS spectrum of undiluted liquid blood substitute, perfluorobron, 
measured via fiber optics at 510.6 nm.
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Figure 4: CFS spectrum of undiluted liquid blood substitute, perfluorobron, 
measured via flow cell at 510.6 nm.
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Results 
The respective CFS™ spectrum of the two perfluorochemicals, 
perfluorobron (C8F17Br) and perfluorodecalin (C10F18), which differed 
by their chemical structure (e.g. linear and cyclic, respectively) (Figure 
1), have been obtained using undiluted blood liquid substitutes at 
determined experimental CFS™ parameters (e.g. excitation wavelength 
in visible or UV area), and were reproduced in different material 
supports for validation studies.
Thereby, using an excitation wavelength in the visible region (510.6 
nm), we show that through:
1. Glass container, the C-F bond optical signature characteristic 
of perfluorobron (PFB) is detectable by CFS™ as a sharp and 
thin peak at 712 cm-1 (emission wavelength). The larger peak 
observed at 288 cm-1 is assigned to the glass container itself 
(Figure 2). 
2. Fiber optics, the specific C-F assignment of PFB is detectable at 
765 cm-1. The larger peak observed at 335 cm-1 is assigned to the 
optical fiber itself (Figure 3). 
3. Flow cell, the C-F bond-contained PFB is obtained at 735 cm-1, 
which is represented by a sharp and thin signal. The larger peak 
observed at 311 cm-1 is assigned to the flow cell itself (Figure 4). 
Taken together, we can conclude that, in our reproducible 
experimental conditions, the C-F assignment of PFB is observed within 
the minimal spectral region of 712-765 cm-1. Further and interestingly, 
DFT calculations have predicted the observed bands assigned as CF2 
scissoring mode to occur at 667 cm-1, thereby confirming and validating 
CFS™ measurements. Indeed, the small difference between the obtained 
experimental and theoretical wavenumber can be attributed to the 
measurement conditions. It is worth noting that fluorine, a hydrogen 
bond acceptor, can be subjected to such interactions owing to the 
different materials support which can perturb slightly the wavelength 
shift of many modes while the calculation has been performed on a 
single molecule in gas phase.
The characterization by CFS of the other liquid blood substitute, 
perfluorodecalin (PFD), was repeated in flow cell as a selected container. 
In brief, we can observe a sharp and very intense optical emission 
signal detectable at 692 cm-1, which is assigned to a symmetrical 
vibration involving the difluoromethyl (-CF2) group (Figure 5). Our 
DFT calculation predicted the C-F signal wavelength at 645 cm-1 which 
also confirms (taking in account the different experimental conditions 
employed) the expected C-F signal wavelength.
Besides, as any of the physical material support used did not 
significantly interfered with the emitted PFB C-F Raman spectrum 
and provided similar data for its physical characterization by CFS, 
we decided to finally use again the flow cell as unique container to 
characterize the two blood substitute products, PFB and PFD, in a UV 
region where both products have been shown to display the maximum 
ultraviolet absorption (271.2 nm). Nevertheless, we noticed that the 
C-F emitted peak intensity of PFB (Figure 6) and PFD (Figure 7) 
compounds were much weaker than those for which the measurements 
have been performed in visible region (510.6 nm) (Figure 4 and 5). 
Eventually, we further observed that the global emission spectral 
signal of PFD obtained by CFS™ was globally enhanced comparatively 
to the PFB´s one, certainly because of the high self-absorbance of 
fluorinated aromatic rings that characterize the PFD structure [14].
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Figure 5: CFS spectrum of undiluted liquid blood substitute, perfluorodecalin, 
measured via flow cell at 510.6 nm. 
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Figure 6: CFS spectrum of undiluted liquid blood substitute, perfluorobron, 
measured via flow cell at 271.2 nm. 
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Figure 7: CFS spectrum of undiluted liquid blood substitute, perfluorodecalin, 
measured via flow cell at 271.2 nm. 
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Taken together, our data show that the physical characterization 
of perfluorocarbons by CFS™ is better performed after excitation in 
the visible region (i.e. at 510.6 nm) than in the ultraviolet region (i.e. at 
271.2 nm), regardless of the type of container used.
Discussion 
Fluid resuscitation is intended to eliminate microcirculatory 
disorders and restore adequate tissue oxygenation. The safety limits 
for a restrictive transfusion policy are given by individual tolerance of 
acute normovolemic anemia. Artificial oxygen carriers, based on PFCs 
or hemoglobin, are attractive alternatives to allogenic red blood cells. 
Indeed, there are many risks involved in allogenic blood transfusions 
(e.g. transmission of infections, delayed postoperative wound healing, 
immune reactions). Regardless of whether artificial oxygen carriers are 
available for routine clinical use, further studies are needed in order 
to show the safety, security and efficacy of these substances for clinical 
practice. 
CFS™ offers a potent tool to characterize PFCs in order, for 
instance, to understand better their metabolism (e.g. pharmacokinetics, 
systemic bioavailability). Indeed, the CFS™ spectrophotometer, based 
on pulsed laser irradiation, is a non-destructive and non-invasive 
method allowing a better resolution of the signals compared to the 
conventional Raman spectroscopy, as already demonstrated earlier13. 
Further, the method allows rapid, sensitive and specific detection as 
well as measurement of C-F bonds without requiring to unravel the 
entire structure of the organo-fluorine product, which besides is also 
possible [13,14]. 
In this work, we showed that it is possible to apply CFS™ technology 
to detect reliably, quickly and cost-effectively blood liquid substitutes 
such as PFB and PFD thanks to the C-F bond assignment. Furthermore, 
our in vitro experimental studies underlined the importance to 
characterize the blood substitutes by CFS™ after photo-excitation at 
510.6 nm (visible region) rather than at 271.2 nm (ultraviolet region) 
regardless of the analytical containers used (e.g. flow cell, glass, optic 
fiber, quartz). 
Conclusions and Perspectives
CFS™ technology demonstrates excellent potential over 
conventional Raman spectroscopy techniques to analyze reliably 
PFCs in vitro. We further aim to apply CFS™ technology combined 
to confocal laser microscope, high pressure liquid-chromatography 
(HPLC) and high-throughput screening (HTS) systems to: (i) 
ensure safety and security of PFCs-based products (e.g. avoidance of 
counterfeited blood substitutes); (ii) qualitatively and quantitatively 
characterize PFCs and F-metabolites in biological fluids using various 
physical-chemical conditions (e.g. pH, temperature); (iii) determinate 
in vivo (e.g. using animal models of disease such sickle cell disease or 
tumor-bearing mice) the presence of PFCs, their localization and, their 
metabolism notably through pharmacokinetic studies; (iv) develop 
PFCs-based nanomaterials for early diagnosis (e.g. “green” enhanced 
imaging) and progressive/controlled-drug delivery (e.g. personalized 
targeted therapy).
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